Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar:24 Suppl 1:196-201.
doi: 10.1111/ggi.14789. Epub 2024 Jan 2.

Associations of polypharmacy with frailty severity and each frailty phenotype in community-dwelling older adults: Itabashi Longitudinal Study on Aging

Kaori Daimaru  1 , Yosuke Osuka  1   2 , Narumi Kojima  1 , Katsuyoshi Mizukami  3 , Keiko Motokawa  1 , Masanori Iwasaki  1   4 , Hiroki Inagaki  1 , Fumiko Miyamae  1 , Tsuyoshi Okamura  1 , Hirohiko Hirano  1 , Shuichi Awata  5 , Hiroyuki Sasai  1
Affiliations

Associations of polypharmacy with frailty severity and each frailty phenotype in community-dwelling older adults: Itabashi Longitudinal Study on Aging

Kaori Daimaru et al. Geriatr Gerontol Int. 2024 Mar.

Abstract

Aim: Although polypharmacy and frailty are concerns in older adults, there is limited understanding of their association, particularly regarding frailty severity and its phenotypes within this population. This study aimed to examine the association between polypharmacy and frailty severity or frailty phenotypes in community-dwelling older Japanese adults.

Methods: This cross-sectional study included 1021 older adults from the Itabashi Longitudinal Study on Aging. Men accounted for 45.4%, and the mean age (standard deviation) was 77.9 (5.1) years. Participants were classified into frail (n = 67), pre-frail (n = 543), and robust (n = 411) groups using the revised Japanese Cardiovascular Health Study criteria. Polypharmacy was defined as using five or more self-reported prescription drugs. Ordinal and binomial logistic regression analyses examined the association between polypharmacy and frailty severity or frailty phenotypes (weight loss, weakness, exhaustion, slowness, and low activity). These models were adjusted for age, sex, body mass index, number of comorbidities, living status, employment status, years of education, as well as drinking and smoking habits.

Results: The prevalence of frailty in participants with and without polypharmacy was 10.1% and 5.0%, respectively. Participants with polypharmacy were more likely to have frailty (adjusted odds ratio [95% confidence interval], 1.89 [1.40-2.57]), weight loss (1.81 [1.00-3.27]), weakness (1.50 [1.08-2.09]), and slowness (2.25 [1.29-3.94]) compared with the no-polypharmacy group.

Conclusions: Polypharmacy was associated with frailty severity and three frailty phenotypes. Longitudinal studies are required to investigate whether polypharmacy can predict the development and progression of frailty. Geriatr Gerontol Int 2024; 24: 196-201.

Keywords: cross‐sectional study; frailty; older adults; phenotype; polypharmacy.

PubMed Disclaimer

References

    1. World Health Organization. Ageing and health [Internet]. 1 October 2022. Available from: https://www.who.int/news-room/fact-sheets/detail/ageing-and-health.
    1. Fried LP, Tangen CM, Walston J et al. Cardiovascular health study collaborative research group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56: M146–M157.
    1. Hoogendijk EO, Afilalo J, Ensrud KE, Kowal P, Onder G, Fried LP. Frailty: implications for clinical practice and public health. Lancet 2019; 394: 1365–1375.
    1. World Health Organization. Medication Safety in Polypharmacy [Internet]. The WHO Document Production Services, Geneva, Switzerland. 2019. Available from: https://www.who.int/docs/default-source/patient-safety/who-uhc-sds-2019-...
    1. Kojima T, Mizokami F, Akishita M. Geriatric management of older patients with multimorbidity. Geriatr Gerontol Int 2020; 20: 1105–1111.

LinkOut - more resources